CL2014003241A1 - Compuestos de n-ariltriazol como antagonistas del receptor de acido lisofosfatidico (lpar); y su uso contra la fibrosis pulmonar. - Google Patents

Compuestos de n-ariltriazol como antagonistas del receptor de acido lisofosfatidico (lpar); y su uso contra la fibrosis pulmonar.

Info

Publication number
CL2014003241A1
CL2014003241A1 CL2014003241A CL2014003241A CL2014003241A1 CL 2014003241 A1 CL2014003241 A1 CL 2014003241A1 CL 2014003241 A CL2014003241 A CL 2014003241A CL 2014003241 A CL2014003241 A CL 2014003241A CL 2014003241 A1 CL2014003241 A1 CL 2014003241A1
Authority
CL
Chile
Prior art keywords
lpar
antagonists
pulmonary fibrosis
acid receptor
lysophosphatidic acid
Prior art date
Application number
CL2014003241A
Other languages
English (en)
Spanish (es)
Inventor
Stephen Deems Gabriel
Yimin Qian
Matthew Michael Hamilton
Achyutharao Sidduri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48628669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014003241(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2014003241A1 publication Critical patent/CL2014003241A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/061,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2014003241A 2012-06-20 2014-11-28 Compuestos de n-ariltriazol como antagonistas del receptor de acido lisofosfatidico (lpar); y su uso contra la fibrosis pulmonar. CL2014003241A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261661953P 2012-06-20 2012-06-20

Publications (1)

Publication Number Publication Date
CL2014003241A1 true CL2014003241A1 (es) 2015-03-20

Family

ID=48628669

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003241A CL2014003241A1 (es) 2012-06-20 2014-11-28 Compuestos de n-ariltriazol como antagonistas del receptor de acido lisofosfatidico (lpar); y su uso contra la fibrosis pulmonar.

Country Status (22)

Country Link
US (1) US20150133512A1 (h)
EP (1) EP2864301A1 (h)
JP (1) JP2015520203A (h)
KR (1) KR20150011389A (h)
CN (1) CN104395299A (h)
AU (1) AU2013279513A1 (h)
BR (1) BR112014030674A2 (h)
CA (1) CA2869564A1 (h)
CL (1) CL2014003241A1 (h)
CO (1) CO7131357A2 (h)
EA (1) EA201492281A1 (h)
HK (1) HK1206339A1 (h)
IL (1) IL236087A0 (h)
IN (1) IN2014DN09352A (h)
MA (1) MA37762B1 (h)
MX (1) MX2014014711A (h)
PE (1) PE20142305A1 (h)
PH (1) PH12014502363A1 (h)
SG (1) SG11201407228PA (h)
UA (1) UA110310C2 (h)
WO (1) WO2013189865A1 (h)
ZA (1) ZA201408167B (h)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2744807A4 (en) 2011-08-15 2015-03-04 Intermune Inc COMPOUNDS AS LYSOPHOSPHIC ACID RECEPTOR ANTAGONISTS
US20140213538A1 (en) * 2013-01-15 2014-07-31 Intermune, Inc. Lysophosphatidic acid receptor antagonists
MX382748B (es) 2013-03-15 2025-03-13 Epigen Biosciences Inc Compuestos heterociclicos utiles para el tratamiento de una enfermedad.
UY36060A (es) 2014-04-02 2015-10-30 Bayer Pharma AG Compuestos de azol sustituidos con amida
RU2689315C2 (ru) 2014-06-27 2019-05-27 Убе Индастриз, Лтд. Соль гетероциклического соединения, замещенного галогеном
WO2017055313A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
WO2017055316A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
WO2018078005A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted azaspiro derivatives as tankyrase inhibitors
WO2018078009A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives
WO2018087126A1 (en) 2016-11-09 2018-05-17 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives as inhibitors of tankyrase
CN107827829A (zh) * 2017-11-07 2018-03-23 大连理工大学 5‑酰胺基‑1,4,5‑三取代的1,2,3‑三氮唑在水相及生物介质中的制备方法
CN107721984A (zh) * 2017-11-07 2018-02-23 大连理工大学 一种新型5‑酰胺基‑1,4,5‑三取代的1,2,3‑三氮唑的制备方法
WO2019126099A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
US11319309B2 (en) 2017-12-19 2022-05-03 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azines as LPA antagonists
US11312706B2 (en) 2017-12-19 2022-04-26 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azines as LPA antagonists
US11180488B2 (en) 2017-12-19 2021-11-23 Bristol-Myers Squibb Company Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists
TW201927778A (zh) 2017-12-19 2019-07-16 美商必治妥美雅史谷比公司 作為lpa拮抗劑之環己基酸三唑唑類
CN111699180B (zh) 2017-12-19 2024-11-29 百时美施贵宝公司 作为lpa拮抗剂的吡唑n-连接的氨基甲酰基环己基酸
EP3728196B1 (en) 2017-12-19 2023-04-05 Bristol-Myers Squibb Company Pyrazole o-linked carbamoyl cyclohexyl acids as lpa antagonists
WO2019126103A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azoles as lpa antagonists
KR102756639B1 (ko) * 2017-12-19 2025-01-16 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헥실 산 이속사졸 아졸
AU2018392324A1 (en) 2017-12-19 2020-08-06 Bristol-Myers Squibb Company Cyclohexyl acid triazole azines as LPA antagonists
KR20210061383A (ko) 2018-09-18 2021-05-27 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로펜틸 산
CN111434653A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 三氮唑类化合物及其制备方法与用途
JP7431961B2 (ja) 2019-11-15 2024-02-15 ギリアード サイエンシーズ, インコーポレイテッド Lpa受容体アンタゴニストとしてのトリアゾールカルバメートピリジルスルホンアミド及びその使用
TWI838626B (zh) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
CN115867556B (zh) 2020-06-03 2025-05-06 吉利德科学公司 Lpa受体拮抗剂及其用途
KR20240005892A (ko) 2021-05-11 2024-01-12 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
KR20240115978A (ko) 2021-12-08 2024-07-26 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
CN115745848A (zh) * 2022-12-07 2023-03-07 上海优合生物科技有限公司 一种氨基胍的加工合成工艺

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159550A2 (en) * 2010-06-14 2011-12-22 Amidra Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist and uses thereof
WO2011159633A1 (en) * 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Inhalable formulations of lysophosphatdic acid receptor antagonists
BR112013014019A2 (pt) * 2010-12-07 2016-09-13 Amira Pharmaceuticals Inc antagonistas do receptor do ácido lisofosfatídico e seus usos
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
EP2744807A4 (en) * 2011-08-15 2015-03-04 Intermune Inc COMPOUNDS AS LYSOPHOSPHIC ACID RECEPTOR ANTAGONISTS
BR112014030685A2 (pt) * 2012-06-20 2017-06-27 Hoffmann La Roche compostos de n-alquiltriazol como antagonistas de lpar

Also Published As

Publication number Publication date
UA110310C2 (uk) 2015-12-10
MA37762B1 (fr) 2018-04-30
IN2014DN09352A (h) 2015-07-17
JP2015520203A (ja) 2015-07-16
IL236087A0 (en) 2015-02-01
SG11201407228PA (en) 2014-12-30
CN104395299A (zh) 2015-03-04
CA2869564A1 (en) 2013-12-27
PH12014502363A1 (en) 2015-01-12
BR112014030674A2 (pt) 2017-06-27
WO2013189865A1 (en) 2013-12-27
MX2014014711A (es) 2015-03-04
HK1206339A1 (en) 2016-01-08
CO7131357A2 (es) 2014-12-01
US20150133512A1 (en) 2015-05-14
ZA201408167B (en) 2015-12-23
MA37762A1 (fr) 2017-07-31
KR20150011389A (ko) 2015-01-30
PE20142305A1 (es) 2015-01-16
AU2013279513A1 (en) 2014-10-16
EP2864301A1 (en) 2015-04-29
EA201492281A1 (ru) 2015-04-30

Similar Documents

Publication Publication Date Title
CL2014003241A1 (es) Compuestos de n-ariltriazol como antagonistas del receptor de acido lisofosfatidico (lpar); y su uso contra la fibrosis pulmonar.
CL2014003243A1 (es) Compuestos de n-alquiltriazol como antagonistas del receptor del acido lisofosfatidico (lpar); usos contra fibrosis pulmonar.
IL277652A (en) Stable aqueous formulations of adlimumab
CL2014003242A1 (es) Compuestos de pirazol sustituidos como antagonistas del receptor del acido lisofosfatidico (lpar); usos contra la fibrosis pulmonar.
DK2882850T3 (da) System for preparation of adipose-derived stem cells
EP2903509A4 (en) PORTABLE HEART MONITOR
IL230913A0 (en) Lysophosphatidic acid receptor antagonists
PL3862010T3 (pl) Zastosowanie akkermansia muciniphila w promowaniu utraty masy ciała
IL226491A0 (en) Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis
CL2014003031A1 (es) Compuestos derivados de uracilo sustituidos biciclicamente; procedimiento de preparacion; composicion farmaceutica; uso para tratar y/o prevenir insuficiencia cardiaca, hipertension pulmonar, epoc, asma, nefropatia, entre otras.
HRP20160250T1 (hr) Postupak za pripravu 2-(2,3-dimetilfenil)-1-propanala s kloracetonom
IL236688B (en) Beta amino acid derivatives as integrin antagonists
EP2925325A4 (en) STABILIZED FORMULATION OF PEMETREXED
CO6950497A2 (es) Compuestos de 1,2,5-oxadiazol sustituidos y su uso como herbicidas
CR20140263A (es) Composicion herbicida que contiene acido de 4-amino-3-cloro-6-(-4-cloro-2-fluor-3-metoxifenil) piridina-2-carboxilico, o los derivados del mismo y fluroxipir, o los derivados del mismo
BR112013012452A2 (pt) uso de dispersões aquosas como primers
CL2015001399A1 (es) Composiciones detergentes acuosas de estructura polimérica.
SMT201500296B (it) Antagonisti del recettore trpm8
PL2836580T3 (pl) Mikrofibrylarna celuloza jako substancja czynna zdolna do odrywania brudu
CR20140343A (es) Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina
ZA201600753B (en) Amide derivatives as lysophosphatidic acid receptor antagonists
BR112014010153A2 (pt) formulação esporicida, lenço e lenço umedecido
BR112013009640A2 (pt) derivados de tetrahidroquinolina usados como ativadores de ampk
ZA201500979B (en) Electrochemical generation of chlorinated urea derivatives
EP2888261A4 (en) ANTAGONISTS OF CHEMOKIN RECEPTORS